Waquar Ahsan | Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Research Excellence Award: Waquar Ahsan

Waquar Ahsan – Jazan University, College of Pharmacy, Saudi Arabia

Waquar Ahsan
Researcher Waquar Ahsan
Affiliation Jazan University
Country Saudi Arabia
Scopus ID 24605168800
Documents 115
Citations 3,288
h-index 33
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-5987-2933

Waquar Ahsan is a pharmaceutical researcher affiliated with the College of Pharmacy at Jazan University, Saudi Arabia. His academic contributions encompass pharmaceutical chemistry, drug discovery, nanomedicine, formulation development and pharmacological investigations. His research profile reflects interdisciplinary engagement with emerging therapeutic technologies and pharmaceutical innovation. His scholarly record provides a foundation for consideration under the Research Excellence Award at the International Top Pharmaceutical Awards. [1]

1. Abstract

This article presents the academic and research contributions of Waquar Ahsan in pharmaceutical sciences, with particular emphasis on drug discovery and development. His documented publications cover nanostructured drug delivery systems, anticancer formulations, molecular interactions and therapeutic applications of pharmaceutical compounds. These research areas demonstrate an interdisciplinary approach connecting pharmaceutical chemistry, formulation science and biomedical research. His scholarly activities provide relevant evidence for recognition of research contributions and scientific advancement. [2]

2. Keywords

Waquar Ahsan; Research Excellence Award; Drug Discovery and Development; Pharmaceutical Chemistry; Nanomedicine; Drug Delivery Systems; Pharmaceutical Formulation; Anticancer Research; Molecular Docking; Pharmacological Research.

3. Introduction

Drug discovery and development involve interconnected scientific disciplines focused on identifying therapeutic candidates, optimizing formulations and investigating their biological properties. Research in these areas contributes to the development of innovative pharmaceutical approaches and improved drug delivery strategies. Waquar Ahsan’s publication record includes investigations addressing pharmaceutical formulations, natural compounds, nanotechnology-based interventions and potential therapeutic applications, reflecting the multidisciplinary character of contemporary pharmaceutical research. [3]

4. Research Profile

According to his ORCID record, Waquar Ahsan is associated with the College of Pharmacy at Jazan University, Saudi Arabia, as an Associate Professor of Pharmaceutical Chemistry. His registered scholarly activities include journal articles and research contributions across pharmaceutical and biomedical disciplines. His ORCID profile also documents his Scopus Author ID and research outputs, supporting the identification and verification of his academic publications. [1]

5. Research Contributions

Additional contributions concern therapeutic deep eutectic systems and pharmaceutical delivery applications. His collaborative research also addresses natural compounds, molecular docking and pharmacological investigations. Such research themes are relevant to exploring formulation optimization, compound characterization and potential therapeutic mechanisms. They demonstrate the connection between pharmaceutical chemistry and emerging approaches to drug discovery and development. [5]

6. Publications

His documented publications include Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ, published in Nanomedicine (2024), and Development of nanobigel system combining apoptosis-inducing daidzein and flaxseed oil for the synergistic treatment of skin cancer, published in the Journal of Drug Delivery Science and Technology (2024). Both publications address nanotechnology-assisted pharmaceutical formulation research. [3] [4]

7. Research Impact

The research record demonstrates contributions across pharmaceutical chemistry, drug delivery, nanomedicine and therapeutic investigations. His collaborative publications provide scientific perspectives on formulation development and potential applications of pharmaceutical compounds. The reported citation indicators further offer measurable evidence of scholarly visibility. Continued research into advanced delivery platforms and therapeutic candidates may contribute to future developments in pharmaceutical and biomedical sciences. [2] [4]

8. Award Suitability

Waquar Ahsan’s research activities demonstrate relevance to the Research Excellence Award through documented publications, interdisciplinary pharmaceutical investigations and contributions to nanotechnology-assisted drug delivery research. His reported bibliometric indicators provide additional quantitative context for academic evaluation. His research profile aligns with the award’s emphasis on scientific contributions, pharmaceutical innovation and scholarly advancement within drug discovery and development. [1] [2]

9. Conclusion

Waquar Ahsan’s academic profile reflects sustained engagement with pharmaceutical chemistry, nanomedicine and drug discovery research. His documented publications demonstrate collaborative contributions to advanced formulations and potential therapeutic applications. The combination of research outputs, interdisciplinary interests and reported scholarly indicators establishes a relevant academic profile for consideration under the Research Excellence Award presented by the International Top Pharmaceutical Awards.

11. References

  1. Elsevier. (n.d.). Scopus author details: Waquar Ahsan, Author ID 24605168800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24605168800
  2. Mangla, B., Mittal, P., Kumar, P., Javed, S., Ahsan, W., and Aggarwal, G. (2024). Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ. Nanomedicine.
    DOI: 10.2217/nnm-2023-0260
  3. Mangla, B., Kaur, A., Kumar, P., Javed, S., Ahsan, W., and Popli, H. (2024). Development of nanobigel system combining apoptosis-inducing daidzein and flaxseed oil for the synergistic treatment of skin cancer. Journal of Drug Delivery Science and Technology.
    DOI: 10.1016/j.jddst.2024.105843
  4. Javed, S., Mangla, B., Sultan, M. H., Almoshari, Y., Sivadasan, D., Madkhali, O. A., and Ahsan, W. (2024). Pharmaceutical applications of therapeutic deep eutectic systems (THEDES) in maximising drug delivery. Heliyon.
    DOI: 10.1016/j.heliyon.2024.e29783
  5. Khalid, A., Khan, W., Zia, K., Azizuddin, Ahsan, W., and collaborators. (2023). Natural coumarins from Murraya paniculata as mixed-type inhibitors of cholinesterases: In vitro and in silico investigations. Frontiers in Pharmacology.
    DOI: 10.3389/fphar.2023.1133809

Shweta Patel | Women Researcher Award | Pharmaceutical

Published on by Top Pharmaceutical

Women Researcher Award

Shweta Patel — Gokul Global University, India

Shweta Patel
Affiliation Gokul Global University
Country India
Scopus ID 59600471600
Documents 17
Citations 25
h-index 3
Subject Area Pharmaceutical
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8893-3248

Shweta Patel is a researcher associated with Gokul Global University, India, whose documented scholarly record includes pharmaceutical and medicinal chemistry research. Her recent work includes heterocyclic compound synthesis, antimicrobial evaluation, antioxidant studies, and ADME-oriented investigations. The available research record also identifies contributions involving green synthesis and computational assessment of chemical compounds.[1] :contentReference[oaicite:0]{index=0}

Abstract

The research profile of Shweta Patel reflects activity across pharmaceutical chemistry, medicinal chemistry, chemical synthesis, antimicrobial research, and computational drug-development approaches. Available records document studies involving pyran, oxadiazole, thiazolidinone, chromene, quinoline, and related heterocyclic frameworks. Several publications combine synthesis and characterization with biological or ADME-oriented evaluation, providing a multidisciplinary basis for pharmaceutical research.[2]

Keywords

Pharmaceutical Chemistry; Medicinal Chemistry; Drug Discovery; Heterocyclic Chemistry; Antimicrobial Research; Antioxidant Activity; ADME Prediction; Green Synthesis; Chemical Synthesis; Pharmaceutical Innovation.

Introduction

Pharmaceutical research increasingly integrates synthetic chemistry with biological screening and computational approaches to identify compounds with potentially useful pharmacological characteristics. Patel’s documented publications reflect this interdisciplinary pattern, particularly through investigations of heterocyclic derivatives and their antimicrobial or antioxidant properties. The research record also includes studies applying ADME prediction and green synthetic methodologies to pharmaceutical chemistry problems.[3]

Research Profile

The available Scopus-linked record identifies Shweta Patel with Scopus Author ID 59600471600, while the supplied ORCID record identifies 33 works across articles, book chapters, and other research outputs. The documented publication history spans at least 2023–2026 and includes journals such as the Journal of Pharmaceutical Innovation, Russian Journal of General Chemistry, Russian Journal of Organic Chemistry, and related scientific publications.[4]

Research Contributions

A recurring research theme is the design and synthesis of heterocyclic compounds followed by structural characterization and biological evaluation. Recent records include pyrazole–oxadiazole–thioacetamide hybrids, 1,8-naphthyridine–thiazolidinone derivatives, chromene–thiazolidinedione hybrids, and oxadiazole thioacetamide derivatives. These studies demonstrate an emphasis on connecting molecular design with antimicrobial activity and ADME-related assessment.[5]

Publications

The publication portfolio includes recent journal articles and earlier studies in synthetic and pharmaceutical chemistry. Documented examples include work on 2H-pyran derivatives, 1,3,4-oxadiazole derivatives, modified 2-oxochromane compounds, 1,4-dihydropyrano[2,3-c]pyrazoles, and 2-amino-4H-pyrans. The record also contains research on environmental applications of functionalized nanoparticles and pharmaceutical sedation comparisons.[4]

Research Impact

The supplied profile records 17 documents, 25 citations, and an h-index of 3 for the award profile. These metrics provide quantitative indicators of scholarly output and citation activity, although bibliometric values can change as databases are updated. The broader ORCID-linked record indicates additional works and research outputs beyond the selected metrics supplied for this recognition page.[4]

Award Suitability

The documented combination of pharmaceutical chemistry publications, heterocyclic synthesis, antimicrobial evaluation, antioxidant investigations, and ADME-focused research provides a clear scholarly basis for consideration within a pharmaceutical research recognition context. The record contains multiple peer-reviewed journal articles with DOI identifiers, allowing individual publications to be independently located and evaluated. Award consideration should be based on the applicable criteria and verified supporting documentation. [4]

Conclusion

Shweta Patel’s documented research activity encompasses several interconnected areas of pharmaceutical and medicinal chemistry, with particular emphasis on synthetic heterocyclic chemistry and biological evaluation. Her publication record includes recent DOI-indexed studies as well as earlier research on green synthesis and antimicrobial compounds. The available identifiers and publication records provide a basis for further scholarly verification and recognition assessment.

References

 

  1. Elsevier. (n.d.). Scopus author details: Shweta Patel, Author ID 59600471600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59600471600
  2. Patel, S. A. (2026). Development of a Novel 1,8-Naphthyridine–Thiazolidinone Derivative: Synthesis, Spectral Characterization, Antimicrobial Profiling, and ADME Prediction. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10426-z
  3. Patel, S. (2026). Structure–Activity Relationship and ADME-Guided Optimization of 4H-Chromene-3-Carbonitrile Derivatives as Promising Antimicrobial Agents. Research Square. https://doi.org/10.21203/rs.3.rs-8718836/v1
  4. Patel, S. (2026). Design and Synthesis of Pyrazole–Oxadiazole–Thioacetamide Hybrids with Antimicrobial and Antioxidant Properties. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10720-w
  5. Patel, S. (2026). Molecular hybridization approach toward quinoline–thiazolidinedione derivatives: synthesis, DPPH radical scavenging activity, and ADME prediction. Journal of the Iranian Chemical Society. https://doi.org/10.1007/s13738-026-03636-2

Onwu Daniel Ocha | Drug Discovery | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Onwu, Daniel Ocha
Affiliation University of Cross River State
Country Nigeria
Google Scholar ID n6jcvPsAAAAJ
Documents 9
Citations 2
h-index 1
Subject Area Drug Discovery
Event International Top Pharmaceutical Awards

Onwu Daniel Ocha – University of Cross River State

Onwu Daniel Ocha is a researcher affiliated with the University of Cross River State (UNICROSS), Calabar, Nigeria. His reported scholarly work is associated with computational biology, bioinformatics, drug discovery, network pharmacology, phytochemical investigation, and computational modelling. The supplied Google Scholar record reports nine documents, two citations, and an h-index of one. The profile also identifies computational biology and bioinformatics among the research areas associated with his scholarly activity.

Abstract

Onwu Daniel Ocha’s research profile reflects interdisciplinary activity connecting computational biology and bioinformatics with pharmaceutical and biomedical investigation. His available publication record includes research on phytochemicals, network pharmacology, computational modelling, biological targets, infectious diseases, and therapeutic investigation. These subjects are relevant to modern drug discovery because computational approaches can support the identification of candidate compounds, molecular targets, pathways, and potential mechanisms of action. His research record therefore demonstrates an emerging connection between computational science and pharmaceutical research. [1]

Keywords

Drug Discovery; Computational Biology; Bioinformatics; Network Pharmacology; Computational Modelling; Molecular Docking; Phytochemicals; Drug Target Identification; Systems Biology; Therapeutic Targeting; Pharmaceutical Research; In-silico Research; Biomedical Informatics.

Introduction

Computational biology and bioinformatics have become important components of modern pharmaceutical research. Computational approaches can be used to examine molecular interactions, biological pathways, disease-associated targets, and candidate therapeutic compounds before or alongside laboratory validation. Network pharmacology is particularly useful for studying complex relationships between compounds, proteins, pathways, and disease mechanisms. These approaches can contribute to the prioritization of potential therapeutic candidates and provide hypotheses for subsequent experimental research [1].

Research Profile

The supplied academic profile identifies Onwu Daniel Ocha with the University of Cross River State (UNICROSS), Calabar, Nigeria. His Google Scholar record reports nine documents, two citations, and an h-index of one. The research areas represented in the supplied profile include computational biology and bioinformatics, while the award profile specifically identifies Drug Discovery as the subject area. This combination places his research at the intersection of computational science and pharmaceutical investigation.[3]

Research Contributions

A notable contribution in the supplied publication record is the study titled In-Silico and Network Pharmacology Analysis of Mimosa invisa Phytochemicals against Testicular Inflammation. The work examines phytochemical compounds using computational approaches to investigate their potential relationships with inflammation-associated biological targets. This research direction is relevant to drug discovery because phytochemicals may provide candidate structures for further pharmacological investigation [3].

Publications

The available publication record demonstrates continuing scholarly activity in computational and biomedical research. Listed publications include studies on Mimosa invisa phytochemicals, biosynthesized silver nanoparticles, Terminalia catappa extracts, Allium cepa bioactive compounds, drug-resistant tuberculosis, Tefairia occidentalis phytocompounds, and computational analysis of antiviral targets. The diversity of these topics indicates an interdisciplinary research approach involving computational methods and biological investigation.[3].

Research Impact

The supplied Google Scholar profile reports two citations and an h-index of one. These bibliometric indicators represent the citation activity recorded by the profile at the time of the supplied document and may change as additional publications are indexed and cited. Therefore, citation indicators should be considered together with publication quality, research relevance, collaboration, and scientific contribution when assessing an emerging researcher.[4].

Award Suitability

The award assessment should nevertheless remain evidence-based and should consider the complete research portfolio, verified publication records, originality, methodological quality, scholarly contribution, collaboration, and the official eligibility criteria established by the award organizers. The available profile demonstrates an emerging publication record rather than providing sufficient evidence for unsupported claims of exceptional impact. This distinction maintains a neutral academic approach to recognition[4].

Conclusion

Onwu Daniel Ocha’s documented research profile demonstrates interdisciplinary activity involving computational biology, bioinformatics, drug discovery, network pharmacology, phytochemicals, and systems biology. The supplied record identifies nine documents, two citations, and an h-index of one, while the listed publications demonstrate research activity across several biomedical and pharmaceutical themes. [1].

References

  1. Onwu, D. O., Uraku, O. H., Agbi, M. T., & Uraku, A. J. (2026). In-silico and network pharmacology analysis of Mimosa invisa phytochemicals against testicular inflammation. In Silico Research in Biomedicine, 2, 100274.
    https://doi.org/10.1016/j.insi.2026.100274
  2. Onwu, D., Edun, S., Asuquo, U., & Bajepade, T. I. (2025). Antidiabetic potential of biosynthesized silver nanoparticles with fresh guava leaf. Covenant Journal of Physical and Life Sciences, 13(2), 1–6.
    https://journals.covenantuniversity.edu.ng/index.php/cjpls/article/view/4978
  3. Onwu, D. O., Kayode, D., Oluwatosin, C. E., Chimaobi, N. G., Johnson, O., et al. (2026). Assessing the effects of aqueous extract of Terminalia catappa on immunoglobulins levels in cyclophosphamide induced immunosuppressant Wistar rats. Next Research, 101441.
    https://doi.org/10.1016/j.nexres.2026.101441
  4. Onwu, D. O., Singh, A., Bajpai, Y., Akinlamilo, A. S., Habiganuchi, A., & Ibikunle, F. O. (2025). Host–pathogen interaction mapping in drug-resistant tuberculosis: A systems biology framework for dual therapeutic targeting. Research Square.
    https://doi.org/10.21203/rs.3.rs-7855974/v1
  5. Ahmad, A., Nnenna, A. O., Mamman, S., Nwokoro, C., Bello, A. M., Nseabasi, M. A., Abdulwakiil, M., Okpe, J., Onwu, D. O., Agbi, M., & Idoko, A. (2025). In-silico network pharmacology and computational modelling of bioactive compounds from Allium cepa targeting downstream protein effectors in diabetes. Research Square.
    https://doi.org/10.21203/rs.3.rs-8181479/v1

Ekaterina Silina | Drug Discovery | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Ekaterina Silina | Drug Discovery | Research Excellence Award

Professor | Sechenov First Moscow State Medical University (Sechenov University) | Russia

Prof. Dr. Ekaterina Silina is a distinguished researcher in materials science, nanotechnology, and biomedical applications, with a strong focus on functional nanomaterials, sensors, and therapeutic platforms. Her work bridges advanced material synthesis with real-world medical and environmental applications, contributing significantly to high-impact interdisciplinary research. She has authored 165 documents, receiving 1,217 citations across 1,004 citing documents, and holds an h-index of 18, reflecting sustained scholarly influence and global research visibility.

Citation Metrics (Scopus)

1300

1000

800

600

400

200

0

Citations
1,217

Documents
165

h-index
18

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Profile

Featured Publications

Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Ataturk University | Turkey 

Prof. Dr. Mine Gülaboğlu is a distinguished scholar in Biochemistry, Pharmacology, and Basic Pharmaceutical Sciences, currently serving as the Head of the Department of Basic Pharmaceutical Sciences at Atatürk University, Faculty of Pharmacy. She completed her Ph.D. in Medical Biochemistry in 2004, following her postgraduate specialization (1990–1993) and undergraduate training in Chemistry (1982–1986), all at Atatürk University.With extensive academic and administrative service, she has held key roles such as Faculty Board Member, Departmental Academic Incentive Evaluation Chair, Performance Evaluation Committee Member, Criteria Committee Member, and Education Committee Member. Her commitment to academic excellence is further demonstrated through numerous jury memberships for professorship, associate professorship, postgraduate examinations, doctoral thesis monitoring, and scientific evaluations.Prof. Dr. Gülaboğlu’s research focuses on health sciences, particularly biochemistry, pharmacology, therapeutics, and pharmaceutical sciences. She has authored impactful research articles in high-ranking journals such as Scientific Reports, Biomedicines, Experimental Eye Research, European Review for Medical and Pharmacological Sciences, and others. Her scientific contributions include investigations into oxidative stress, drug-induced toxicity, protective biochemical agents, nanoformulations, and molecular mechanisms underlying disease pathology.Over her career, she has completed numerous certifications, trainings, and specialized courses in molecular techniques, pharmacology, chemometrics, laboratory quality systems, education management, energy efficiency, environmental sustainability, and occupational safety. She is also proficient in English at an intermediate level.A dedicated educator, Prof. Dr. Gülaboğlu teaches a wide range of courses across undergraduate, postgraduate, and doctoral levels, including Biochemistry, Protein Separation Techniques, Vitamins and Coenzymes, Metabolism, Research Methods, and Project Courses.Prof. Dr. Mine Gülaboğlu continues to contribute profoundly to scientific research, education, and academic leadership in Türkiye, shaping future generations of pharmaceutical and biomedical scientists.

Profile: Google Scholar

Featured Publications

Altuner, D., Gulaboglu, M., Yapca, O. E., & Cetin, N. (2013). The effect of mirtazapine on cisplatin-induced oxidative damage and infertility in rat ovaries. The Scientific World Journal, 2013(1), 327240.

Bilici, M., Ozturk, C., Dursun, H., Albayrak, F., Saglam, M. B., Uyanik, A., … (2009). Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters. Digestive Diseases and Sciences, 54(9), 1868–1875.

Gulaboglu, M., Borekci, B., & Delibas, I. (2010). Urine iodine levels in preeclamptic and normal pregnant women. Biological Trace Element Research, 136(3), 249–257.

Gulaboglu, M., Borekci, B., & Halici, Z. (2007). Placental tissue iodine level and blood magnesium concentration in pre-eclamptic and normal pregnancy. International Journal of Gynecology & Obstetrics, 98(2), 100–104.

Coskun, R., Turan, M. I., Turan, I. S., & Gulapoglu, M. (2014). The protective effect of thiamine pyrophosphate, but not thiamine, against cardiotoxicity induced with cisplatin in rats. Drug and Chemical Toxicology, 37(3), 290–294.

Gulaboglu, M., Yildiz, L., Celebi, F., Gul, M., & Peker, K. (2005). Comparison of iodine contents in gastric cancer and surrounding normal tissues. Clinical Chemistry and Laboratory Medicine, 43(6), 581–584.

Özer, A. K., Gülaboğlu, M., & Bayrakçeken, S. (2000). Physical structure and chemical and mineralogical composition of the Mazıdağı (Turkey) phosphate rock. Industrial & Engineering Chemistry Research, 39(3), 679–683.

Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U. P., Yang, X., Liu, Z., Altwegg, K. A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H. B., Ford, A., Dick, E. J., Jr., Hill, R. H., Jr., & VandeBerg, J. L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H. B., Kesavaram, N., Das, B., Garfield, R., Shi, S. Q., … Edwards, D. P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., … Nair, H. B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N. M., Nair, H. B., Liu, Y. G., Kirma, N. B., Binkley, P. A., Kumar, S., … Tekmal, R. R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication Profile 

Orcid

Education 

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

Experience 

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and Honors 

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research Focus 

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

E Marimuthu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. E. Marimuthu | Drug Discovery and Development | Best Researcher Award

Professor at Arunachal University of Studies | Ayya Nadar Janaki Ammal College | Madurai Kamaraj University | India

Dr. E. Marimuthu is a dedicated researcher and academician specializing in plant biotechnology, microbiology, and molecular biology. With over 15 years of experience in research and education, he has made significant contributions through patents, microbial sequencing, and ethnobotanical surveys. His work focuses on endangered species conservation, natural IAA production, and nanomedicine applications for cancer. Dr. Marimuthu currently serves as a Professor at Arunachal University of Studies. His multidisciplinary efforts bridge traditional knowledge with modern scientific innovations, making him a standout figure in applied life sciences and pharmaceutical biotechnology.

Publication Profile 

Scopus 

Education

Dr. Marimuthu earned his Ph.D. from Madurai Kamaraj University in 2017, focusing on the in vitro conservation of endangered tree species in the Southern Western Ghats . He completed his M.Phil. and M.Sc. from Ayya Nadar Janaki Ammal College, conducting ethnomedicinal surveys and plant growth hormone studies. His academic foundation began with a B.Sc. in Botany. Each academic milestone has been rooted in biodiversity conservation and plant-microbe interactions, establishing a strong base for his later patents and microbial gene discoveries .

Experience

Dr. Marimuthu has held various academic and research roles: Professor and Associate Professor at Arunachal University of Studies (2023–present), Assistant Professor at Sri Vidya Mandir and Vivekanandha Colleges, and Associate Scientist at Aakash Green Research Pvt. Ltd. Earlier, he served as a JRF at TBGRI, Kerala  and Technical Assistant at Kalasalingam University. His experience spans plant tissue culture, cell line work, and microbial molecular studies. With deep involvement in both lab and field research, he has nurtured innovations from concept to patent, while also mentoring students and contributing to curriculum development.

Awards 

Dr. E. Marimuthu is a prolific innovator with 8 Indian patents and 2 Canadian patents, showcasing breakthroughs in nanomedicine, cancer immunotherapy, and plant-based biotechnology . His bacterial gene sequences are submitted to NCBI, emphasizing novel microbial discoveries from unique ecological niches. Recognized nationally and internationally for his translational research, he has pioneered techniques that merge traditional plant knowledge with high-end scientific platforms. Though specific named awards are not listed, his patent record and academic promotions signify a distinguished and respected trajectory in bioscience innovation and interdisciplinary research.

Research Focus 

Dr. Marimuthu’s research emphasizes plant tissue culture, natural growth hormone production, ethnomedicinal conservation, and nanotechnology-enhanced drug delivery . He explores molecular markers for documenting genetic diversity and has successfully isolated bacterial strains producing Indole-3-acetic acid (IAA) to promote plant growth . He integrates ethnobotanical knowledge with biotechnological advancements to develop eco-friendly, scalable solutions for agriculture and medicine. His cutting-edge work in cancer-targeting mesenchymal stem cell therapy, as well as nano-immunotherapy, reflects a visionary outlook on the future of personalized medicine and sustainable pharmacology.

Publication Top Notes

Title: Chemical profiling and in silico molecular docking studies of phytochemicals from Hydnocarpus macrocarpa Warb: A GC–MS, FTIR, and physico-chemical analysis
Journal: Journal of Molecular Structure
Year: 2025

Conclusion

Dr. E. Marimuthu is an outstanding candidate for the Best Researcher Award, showcasing a rare combination of field knowledge, lab precision, patent-oriented innovation, and a commitment to both fundamental and applied science. His work contributes significantly to biotechnology, pharmacology, environmental microbiology, and regenerative agriculture.

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Prof. Dr. Reda Abdel-Hameed, University of Hail, Egypt

Prof. Dr. Reda Abdel-Hameed is a distinguished chemist specializing in applied physical chemistry. He earned his B.Sc. (1998), M.Sc. (2003), and Ph.D. (2006) from Al-Azhar University, Cairo. With over two decades in academia, he has served as a professor at Al-Azhar University and an associate professor at the University of Hail, Saudi Arabia. His prolific research includes 134 published papers on nanotechnology, drug design, and environmental chemistry. A leader in scientific innovation, he continues to shape the future of chemistry through groundbreaking studies and mentorship.

Publication Profile

Google Scholar

Education

Prof. Dr. Reda Abdel-Hameed 🎓 is a distinguished chemist with a strong academic background. He earned his B.Sc. in Chemistry in 1998 with an Excellent with Honor degree 🏅, followed by an M.Sc. in Applied Organic Chemistry in 2003 and a Ph.D. in Applied Physical Chemistry in 2006. His academic career began as a Demonstrator at Al-Azhar University (1998-2003) and progressed to Lecturer (2003-2006), Assistant Professor (2006-2012), and Associate Professor (2012-2017). He also served at Hail University, KSA (2009-2012). Since 2017, he has been a Full Professor at Al-Azhar University, contributing significantly to the field of chemistry 🔬.

Experience 

Prof. Dr. Reda Abdel-Hameed 📚 has an extensive teaching portfolio in chemistry across Al-Azhar University and Hail University. At Al-Azhar, he has taught courses in Physical Chemistry, Electrochemistry, Polymer Science, Industrial Chemistry, and more 🔬. At Hail University, he covered Applied Physical Chemistry, Quantum Chemistry, Medical Chemistry, and Petroleum Chemistry ⛽. Additionally, he played a key role in developing course specifications and descriptions. His contributions extend to authorship, with books like Introduction to Organic Chemistry, Applied Electrochemistry, and Nanocomposites as Corrosion Inhibitors 📖. His dedication to chemistry education continues to inspire students worldwide 🌍.

Awards

Prof. Dr. Reda Abdel-Hameed 🌍 is a globally recognized scientist, ranked among the world’s top 2% by Stanford University and Elsevier from 2019 to 2023 📊. His excellence in academia has earned him numerous accolades, including the Ideal Student Prize (1996-1997) 🏆, the Faculty of Science Award for Academic Affairs (2012), and the Excellence in Teaching Award (2017) 🎓. He was also honored for integrating technology into higher education (2010) and recognized as the Best Coordinator for Student Activities at Hail University (2016). A proud member of the Royal Society of Chemistry (RSC) 🔬, he continues to make remarkable contributions.

Research Focus

Prof. Dr. Reda S. Abdel-Hameed specializes in corrosion science and electrochemical applications ⚡🔬. His research focuses on developing corrosion inhibitors 🛡️ for metals, particularly in acidic and marine environments. He explores green chemistry approaches 🌱, including eco-friendly inhibitors derived from expired drugs 💊, polymers 🏗️, and heterocyclic compounds 🧪. His work advances electrochemical techniques for evaluating materials’ durability and protection in industrial applications 🏭. With significant contributions to nanotechnology-based inhibitors 🧬 and adsorption studies, his research benefits sectors like petrochemicals, metallurgy, and coatings 🏗️. His expertise in analytical electrochemistry helps mitigate corrosion-related challenges, ensuring sustainability and efficiency.

Publication Top Notes

Analytical application using modern electrochemical techniques

Ranitidine drugs as non-toxic corrosion inhibitors for mild steel in hydrochloric acid medium

Preparation of green cardanol-based epoxy and hardener as primer coatings for petroleum and gas steel in marine environment

Aminolysis of polyethylene terephthalate waste as corrosion inhibitor for carbon steel in HCl corrosive medium

Effect of expired drugs as corrosion inhibitors for carbon steel in 1M HCL solution

2-(2, 6-dichloranilino) phenyl acetic acid drugs as eco-friendly corrosion inhibitors for mild steel in 1M HCl

Expired Voltaren drugs as corrosion inhibitor for aluminium in hydrochloric acid

Nano-composite as corrosion inhibitors for steel alloys in different corrosive media

Corrosion inhibition and adsorption properties of some heterocyclic derivatives on C-steel surface in HCl